Diabetes: Freedom Meditech lands $7M to support non-invasive eye-based exams
Freedom Meditech plans to use its newly raised $7 million in Series B funding to forward its eye-based diabetes management suite, including an FDA-cleared diagnostic and a glucose monitor still under development.
Freedom Meditech roped in $7 million in a Series B financing round in support of 2 diagnostic products for diabetes management, 1 already on the shelves and 1 still on the bench.
The fundraising was joined by new and returning investors, including funders who participated in a $2.5 million round in 2009. Since Freedom Meditech's founding in 2006, private investors have kicked in more than $10 million to support the company's flagship biomicroscope technology, according to a press release.